Stay updated on Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial
Sign up to get notified when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.

Latest updates to the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page
- Check6 days agoChange DetectedNew Study Status entry added to the record history. The page revision updated to v3.4.3 and the previous v3.4.2 revision was removed.SummaryDifference0.3%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA new revision entry 'Revision: v3.4.2' was added to the history, and a government funding/operating-status notice was removed.SummaryDifference0.5%

- Check41 days agoChange DetectedAdded a site-wide notice about funding and operating status, and updated the revision to v3.4.1, replacing the previous revision note v3.4.0.SummaryDifference0.5%

- Check48 days agoChange DetectedThe history page now includes a glossary option and color-coded indicators for additions and deletions, plus a revision banner (v3.4.0). The text 'No FEAR Act Data' appears with capitalization changes and the revision reference updated from v3.3.4 to v3.4.0.SummaryDifference0.7%

- Check56 days agoChange DetectedRevision v3.3.4 was added and revision v3.3.3 was removed from the record, indicating administrative updates to the study history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page history now shows a new release note: Revision: v3.3.3 was added, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.